Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Principal Financial Group Inc. trimmed its stake in Insulet Co. (NASDAQ:PODD – Free Report) by 0.3% during the fourth quarter ...

Insulet forecasts total company revenue growth of 16%-20% for 2025, with Omnipod revenue growth projected at 17%-21%. U.S. Omnipod revenue is expected to grow 16%-20%, driven by the continued ramp-up ...

The company produces and sells Omnipod, an automated insulin delivery device, which works without the need for external ...

Insulet’s Q4 revenue hit $597.5 million, up 17.2%, beating the $582.81 million consensus. Omnipod revenue climbed 16.9% to $585.7 million, with international sales up 33.5%. Get two weeks of ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Insulet Corp (PODD) surpasses $2 billion in revenue with strong Omnipod 5 demand, while navigating pricing headwinds and ...

Insulet (NASDAQ:PODD – Get Free Report) had its price objective boosted by analysts at Piper Sandler from $285.00 to $310.00 ...

The company produces and sells Omnipod, an automated insulin delivery device, which works without the need for external tubing typically associated with conventional pumps and eliminates the need ...

For the year ending December 31, 2025, the Company expects revenue growth of 16% to 20%. Revenue growth ranges by product line are: Total ...

The figure surpassed the Zacks Consensus Estimate by 1.9%. Insulet’s total Omnipod revenues of $585.7 million reflected an increase of 16.9% year over year and 16.8% at CER. International ...